Discovery and validation of an early post-transplant biomarker predictive of chronic kidney disease in liver transplant recipients
AssigneeNorthwestern University
InventorsJosh Levitsky, Michael M. Abecassis
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for predicting, inhibiting, and treating chronic kidney disease (CKD) in a subject that that is preparing to undergo a liver transplant. The methods may include detecting a protein biomarker in a serum sample from the subject prior to the subject being administered a liver transplant procedure and/or after the subject has been administered the liver transplant procedure. Suitable protein markers for the disclosed methods may include but are not limited to osteopontin (OPN) and/or tissue inhibitor of metalloproteases 1 (TIMP1).
Claims15
A method comprising:
- (a) detecting osteopontin (OPN) and/or tissue inhibitor of metalloproteinases 1 (TIMP1) in a serum sample from a subject;
- and subsequently
- (b) after the subject has been administered a liver transplant procedure, measuring renal function in the subject.
A method comprising:
- (a) (i) detecting osteopontin (OPN) and/or tissue inhibitor of metalloproteinases 1 (TIMP1) in a serum sample from a subject, and (ii) measuring renal function in the subject;
- and subsequently
- (b) after the subject has been administered a liver transplant procedure, (i) detecting osteopontin (OPN) and/or tissue inhibitor of metalloproteinases 1 (TIMP1) in a serum sample from a subject, and (ii) measuring renal function in the subject.
A kit comprising:
- (a) components for detecting osteopontin (OPN) and/or tissue inhibitor of metalloproteinases 1 (TIMP1) in a serum sample from a subject;
- and
- (b) components for measuring renal function in the subject.
Dependencies are inferred from the claim text.